An Innovative Probiotic Product With Antiallergic Properties

Atopic Dermatitis Clinical Trial

Official title:

An Innovative Probiotic Product With Antiallergic Properties. The Effectiveness of a Mixture of Lactobacillus ŁOCK Strains in Children With Atopic Dermatitis - Multicentre, Randomized, Double-blind Placebo Controlled Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04738565
• Other study ID #: N R12-0101-10/2011
• Status: Completed
• Phase: N/A
• Start date: June 1, 2012
• Est. completion date: December 31, 2015

Study information

• Verified date: February 2021
• Source: Children's Memorial Health Institute, Poland
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Allergic diseases are currently one of the most important problem in medicine. Research confirms that probiotics administered during the formation of the intestinal ecosystem and the maturation of the immune system can positively influence the development of antiallergic mechanisms. The aim of the present randomized, double-blind, placebo controlled study was to evaluate the efficacy of the mixture of probiotic Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908, and Lactobacillus casei ŁOCK 0919 in children up to the age 2 with atopic dermatitis and food allergy to cow's milk proteins. Children received the mixture of Lactobacillus strains for 3 months every day in the daily dose of a billion bacteria or a placebo (maltodextrin). Primary outcomes included the effects of probiotic treatment on the severity of symptoms assessed with SCORing atopic dermatitis (SCORAD) index. Secondary endpoints included assessment of total IgE and selected cytokine levels. Cytokines were evaluated in supernatants obtained from peripheral blood cultures of randomly selected 20 patients from each group. The primary and secondary outcomes were assessed at 3 time points: at baseline, after the finishing the administration of probiotic/placebo, and after 9 months of follow up.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: December 31, 2015
• Est. primary completion date: December 31, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Month to 24 Months

Eligibility

Inclusion Criteria:

• diagnosis of atopic dermatitis according to Hanifin and Rajka criteria,
• age under 2 years (24 months)
• the SCORAD index >10
• suspected allergy to cow's milk protein

Exclusion Criteria:

• acute infections of skin,
• presence of other severe diseases
• treatment with systemic corticosteroids
• treatment with antibiotics for at least 6 weeks prior to study enrollment
• use of probiotics for the last 6 weeks prior to study enrollment

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema
• Effects of Probiotics
• Food Allergy
• Food Hypersensitivity

Intervention

Dietary Supplement:
• Probiotic preparation
The mixture of Lactobacillus rhamnosus LOCK 0900, Lactobacillus rhamnosus LOCK 0908 and Lactobacillus casei LOCK 0919 administered once a day at a dose of one billion for 3 months.
• Maltodextrin
Maltodextrin comparable in color, texture and taste to the probiotic mixture administered once a day for 3 months.

Locations

Country	Name	City	State
Poland	The Children's Memorial Health Institute	Warsaw

Sponsors (1)

Lead Sponsor	Collaborator
Children's Memorial Health Institute, Poland

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in severity of atopic dermatitis symptoms assessed with the use the SCORAD index	The SCORAD index consists of the interpretation of the extent of the disorder (A: according to the rule of nines; 20% of the score), the intensity composed of six items (B: erythema, oedema /papules, effect of scratching, oozing /crust formation, lichenification and dryness; 60% of the score; each item has four grades: 0,1, 2, 3) and subjective symptoms (C: itch, sleeplessness; 20% of the score). Both subjective items are graded on a 10-cm visual analogue scale.; The SCORAD index formula is: A /5 + 7B/2 + C. In this formula A is defined as the extent (0-100), B is defined as the intensity (0-18) and C is defined as the subjective symptoms (0-20). The maximum SCORAD score is 103.	From baseline at 3 months of intervention and 9 months of follow up
Primary	Changes in proportion of children with improvement or worsening of atopic dermatitis symptoms	Atopic dermatitis symptoms were assessed with the use of the SCORAD index. It was assumed that a drop >30% in the SCORAD index compared with baseline was associated with a clinically meaningful improvement. A drop<30% was associated with worsening.	From baseline at 3 months of intervention and 9 months of follow up
Secondary	Changes in the level of total IgE	Total IgE level was measured using the ImmunoCap system according manufacturer's instruction.	From baseline at 3 months of intervention and 9 months of follow up
Secondary	Changes in the level of selected cytokines	The level of proinflammatory Th1 cytokines (e.g. interferon-gamma, interleukin-12), regulatory cytokines (e.g. intreleukin-10) or proallergic Th2 cytokines (e.g. interleukin-5) were measured in the supernatants obtained from the peripheral blood cultures with the use of ELISA techniques.	From baseline at 3 months of intervention and 9 months of follow up